Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia | Zendy

Hagop Kantarjian | Zendy; Anthony S. Stein | Zendy; Nicola Gökbuget | Zendy; Adele K. Fielding | Zendy; Andre C. Schuh | Zendy; JosepMaría Ribera | Zendy; Andrew H. Wei | Zendy; Hervé Dombret | Zendy; Robin Foà | Zendy; Renato Bassan | Zendy; Önder Arslan | Zendy; Miguel Á. Sanz | Zendy; Julie Bergeron | Zendy; Fatih Demırkan | Zendy; Ewa LechMarańda | Zendy; Alessandro Rambaldi | Zendy; Xavier Thomas | Zendy; Heinz-August Horst | Zendy; Monika Brüggemann | Zendy; Wolfram Klapper | Zendy; Brent L. Wood | Zendy; A. Fleishman | Zendy; Dirk Nagorsen | Zendy; Christopher P. Holland | Zendy; Zachary Zimmerman | Zendy; Max S. Topp | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Author(s) -

Hagop Kantarjian,

Anthony S. Stein,

Nicola Gökbuget,

Adele K. Fielding,

Andre C. Schuh,

JosepMaría Ribera,

Andrew H. Wei,

Hervé Dombret,

Robin Foà,

Renato Bassan,

Önder Arslan,

Miguel Á. Sanz,

Julie Bergeron,

Fatih Demırkan,

Ewa LechMarańda,

Alessandro Rambaldi,

Xavier Thomas,

Heinz-August Horst,

Monika Brüggemann,

Wolfram Klapper,

Brent L. Wood,

A. Fleishman,

Dirk Nagorsen,

Christopher P. Holland,

Zachary Zimmerman,

Max S. Topp

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1609783

Subject(s) - blinatumomab , medicine , chemotherapy , hazard ratio , acute lymphocytic leukemia , oncology , leukemia , confidence interval , lymphoblastic leukemia

Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials that showed efficacy and manageable toxic effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research